A selective Δ6 desaturase inhibitor that displays selectivity over Δ5 and Δ9 desaturases

A proton pump inhibitor that reduces stomach acid secretion by inhibition of the H+/K+-ATPase in the parietal cells.

A potent, specific acyl protein thioesterase 2 (APT-2, LYPLA2) inhibitor with IC50 of 144 nM and Ki of 120 nM, >20-fold selectivity over APT-1 and serine hydrolase enzyme family.

A potent, selective, allosteric and oral mGluR1 antaognist with IC50 of 2.6 and 2.3 nM for human and rat mGluR1, respectively.

A potent, selective inhibitor of phosphodiesterases PDE4 with IC50 of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.

A potent, selective and orally bioavailable TRPV1 receptor antagonist with IC50 of 65 nM and 102 nM for hTRPV1 and rTRPV1, respectively.

A potent, orally active pan-inhibitor of HIF prolyl hydroxylase (HIF-PHD) with IC50 of 1.0,1.0, and 14 nM for HIF-PHD1, 2, and 3, respectively.

A potent PD-1/PD-L1 interaction inhibitor with IC50 of 2.25 nM in a homogenous time-resolved fluorescence binding assay..

A potent and selective GC-C agonist (Ki=1.23-1.64 nM) that elicits pharmacological effects locally in the gastrointestinal tract.

A potent and highly specific MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM.

A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.

A novel stearoyl-CoA desaturase1 (SCD1) inhibitor.The compound exhibited robust in vivo activity with dose-dependent desaturation index lowering effects.

A non-selective group I/group II metabotropic glutamate receptor (mGluR) antagonist..

A cell-permeable synthetic peptide inhibitor of Bax conformational change and mitochondrial translocation.

A 419259 3Hcl is an apoptosis inducing agent that inhibits Src family kinases (c-Src).

8-Bromo-cAMP is a cell perbeable cyclic AMP (cAMP) analog and a PKA activator.

6-Thioguanine(6-TG) belongs to the thiopurine family of drugs that also include mercaptopurine and azathioprine, which are examples of antimetabolites; it is a purine analogue of the nucleobase guanine.

5-Iodotubercidin (Itu) has been shown to inhibit mitogen-activated protein kinase (ERK2) (Ki = 525 nM), adenosine kinase (ADK) (Ki = 30 nM), casein kinases 1 & 2 (CSNK1A1 & CSNK2A1), protein kinase A (PKA) and insulin receptor kinase (IC50 ranging from 0.

5-Formyl-2-pyrimidinecarbonitrile is a chemical intermidate..

3PO is a PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase) inhibitor; reduces glycolytic flux and suppresses glucose uptake.

3-Cyano-7-ethoxycoumarin is a fluorescent P450 substrate (excitation/emission wavelengths = 408/455 nm); metabolized to cyano-hydroxycoumarin.

2-NBDG is a fluorescent indicator for direct glucose uptake measurement and also is an indicator of cell viability.

1-methyl-7-nitroisatoic anhydride is a reagent that detects local nucleotide flexibility, for probing 2'-hydroxyl reactivity.

1-EBIO is an Epithelial KCa channel activator. Promotes ESC differentiation into cardiomyocytes.

1-(Ethoxycarbonylmethyl)-6-methoxyquinolinium (MQAE) is a fluorescent indicator dye that can be used to measure intracellular and extracellular chloride concentrations (absorption/emission max: 350/460 nm).

Capadenoson is a selective agonist of adenosine-A1 receptor.

CSRM617 (CSRM-617) is a small-molecule inhibitor of the transcription factor ONECUT2 (OC2) with Kd of 7.43 uM in SPR assays, binds to OC2-HOX domain directly.

CYN 154806 is a potent and selective somatostatin sst2 receptor antagonist. pIC50 values are 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.

Efpeglenatide is a new once-2eekly GLP-1 Injection for Type 2 Diabetes

BTdCPU is an activator of HRI. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2α kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies.